Cytokine

Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024

Retrieved on: 
torsdag, maj 30, 2024
Partnership, Proteomics, Economics, MS/MS, Plasma, Protein, Cytokine, Drug development, Conference, Research, Proteome, Chemokine, WP, Drug discovery, Biomarker, Software, Society, ASMS, Inflammation, Mass spectrometry, Television

P2-based plasma proteomics can be used for human or for animal-model proteomics studies and clinical research.

Key Points: 
  • P2-based plasma proteomics can be used for human or for animal-model proteomics studies and clinical research.
  • This novel P2 plasma proteomics method achieves a proteome coverage of 7,000 proteins in a previously published five-cancer plasma sample set, demonstrating highest reproducibility, unprecedented enrichment of low abundant proteins, and unparalleled throughput on Bruker timsTOF® HT mass spectrometers.
  • “With our proprietary P2 Plasma Enrichment method, Biognosys can now significantly enhance the depth and throughput in plasma proteomics beyond what existing methods could achieve,” explains Dr. Oliver Rinner, CEO and founder of Biognosys.
  • Under a previously announced strategic partnership of Biognosys and Alamar Biosciences , Biognosys will now also offer the optional combination of P2-based mass spectrometry plasma proteomics with Alamar’s targeted, mid-plex ultra-high sensitivity NULISA proteomics panels.

Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting

Retrieved on: 
onsdag, maj 29, 2024
McCormick Place, LPS, Patient, Pharmacokinetics, Plasma, Cytokine, Therapy, Blood, Chemokine, Viral, Poster, Society

The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data will be presented.

Key Points: 
  • The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data will be presented.
  • The data presented include the pharmacokinetics and immune response observed in both cohorts in the ongoing Phase 1 trial for Decoy20.
  • Adverse effects were generally tolerable and resolved with or without treatment within 90 minutes to 3 days.
  • We continue the Phase 1 clinical trial with the first multi-dose cohort and expect to provide updates on progress throughout the year.”

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Retrieved on: 
onsdag, maj 29, 2024
Research, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, EBV, Patient, Cell, Epstein–Barr virus, Phenotype, ISCT, Toxicity, SLE, Cytokine, CD19, International Society, ATRA, Cancer, Autoimmunity, PDT, IL-6, NHL, Inflammation, Lupus nephritis, Annual general meeting, Vaccine

Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells.

Key Points: 
  • Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells.
  • The data will be presented in a poster session at the International Society for Cell & Gene Therapy (ISCT) 2024 Annual Meeting taking place May 29 to June 1, 2024, in Vancouver, Canada.
  • ATA3219 consists of allogeneic CD19-directed CAR EBV T cells that have been optimized to offer a potential best-in-class profile and off-the-shelf availability.
  • “We are pleased to share promising preclinical data that shows ATA3219 mediates robust B-cell depletion against SLE and multiple sclerosis patient derived immune cells.

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Retrieved on: 
onsdag, maj 22, 2024
Oral medicine, Patient, Immunoglobulin E, DDW, Lung, Doctor of Philosophy, American Thoracic Society, Cytokine, Eosinophilic esophagitis, Dupilumab, Therapy, Histology, Asthma, Phase 1, STAT6, Chemokine, ATS, TPD, Gastrointestinal disease, Inflammation, Resource, HDM, Annual general meeting, Pharmaceutical industry

WATERTOWN, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the presentation of additional preclinical data for KT-621, a potent, selective, oral heterobifunctional degrader of STAT6, at the American Thoracic Society (ATS) Annual Meeting in San Diego, California. The featured data demonstrate activity of KT-621 comparable to a saturating dose of the IL-4Rα antibody, dupilumab, in an asthma efficacy model which demonstrated that KT-621 robustly inhibited all the tested cytokines, chemokines, and cell infiltrates involved in TH2 inflammation in asthma. The Company shared additional new histology data showing amelioration of lung remodeling after low, daily oral doses of KT-621 that was comparable to dupilumab. These data highlight the compelling profile of KT-621 as a potential oral treatment for asthma and other TH2 respiratory diseases. Kymera intends to initiate Phase 1 testing for KT-621 in the second half of 2024 and expects data from the Phase 1 trial to be reported in the first half of 2025.

Key Points: 
  • The Company shared additional new histology data showing amelioration of lung remodeling after low, daily oral doses of KT-621 that was comparable to dupilumab.
  • These data highlight the compelling profile of KT-621 as a potential oral treatment for asthma and other TH2 respiratory diseases.
  • In addition, at low daily oral doses, preclinical studies with KT-621 demonstrated near full in vivo STAT6 degradation in disease-relevant tissues that was well-tolerated.
  • Copies of both the ATS and DDW poster presentations are available in the Resource Library section of Kymera's website.

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

Retrieved on: 
tisdag, maj 21, 2024
Transfer, IBD, DDW, UC, Colitis, Session, Cytokine, IND, Therapy, MGD, Inflammation, Autoimmunity, VAV1, Ulcerative colitis, Poster, Inflammatory bowel disease, Vaccine

BOSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at Digestive Disease Week (DDW) 2024, being held May 18-21 in Washington, D.C. The data showed that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis. VAV1 is a key signaling protein downstream of both the T-and B-cell receptors and its degradation has potential to treat multiple T-cell and/or Th17 mediated autoimmune and inflammatory diseases, including ulcerative colitis (UC).

Key Points: 
  • The data showed that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis.
  • “VAV1 is a well-validated target with significant therapeutic potential in autoimmune and inflammatory diseases but is generally considered undruggable via conventional modalities.
  • These promising preclinical data support our hypothesis that VAV1 is an important target in inflammatory bowel disease (IBD) and also demonstrate MRT-6160's ability to potentially address the underlying disease biology and provide therapeutic benefit,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • MRT-6160 was shown to inhibit disease progression, prevent colon inflammation, and reduce pro-inflammatory cytokine production in a murine T-cell transfer model of colitis.

Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

Retrieved on: 
torsdag, maj 16, 2024
NCT, Plasma, Health, Cytokine, Clinical trial, Trial of the century, Safety, Society, Research, PD-1, Carcinoma, Gene silencing, Vaccine

The data is being presented in three posters at the annual meeting of the Society for Investigative Dermatology (SID) this week in Dallas, Texas.

Key Points: 
  • The data is being presented in three posters at the annual meeting of the Society for Investigative Dermatology (SID) this week in Dallas, Texas.
  • PH-762 is an INTASYL compound that silences PD-1, a protein that inhibits T cells' ability to kill cancer cells.
  • The preclinical profile of PH-762 supports the ongoing clinical development of the compound for the treatment of cutaneous malignancies.
  • PH-762 is currently being studied in a US clinical trial to assess safety and efficacy in specific skin cancers (NCT 06014086).

Indapta Therapeutics to Highlight its g-NK Cell Platform for the Treatment of Cancer and Autoimmune Disease in a Plenary Session at New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference

Retrieved on: 
torsdag, maj 23, 2024
Research, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Patient, ADCC, Acute leukemia, Epstein–Barr virus, Food, Cytokine, NK, Clinical trial, Therapy, IND, Disease, Autoimmune disease, Conference, MD, Multiple sclerosis, Cancer, Multiple myeloma, Cytomegalovirus, CMV, Cell, NKG2C, Vaccine

In his talk, Dr. Frohlich will summarize the differentiated mechanisms of target cell killing for Indapta’s lead clinical program, IDP-023, a g-NK cell therapy product.

Key Points: 
  • In his talk, Dr. Frohlich will summarize the differentiated mechanisms of target cell killing for Indapta’s lead clinical program, IDP-023, a g-NK cell therapy product.
  • These mechanisms include highly robust antibody-dependent cell mediated cytotoxicity (ADCC), the targeting of HLA-E expressing cells via the NKG2C receptor, and the inherent anti-viral activity of g-NK cells.
  • Indapta is currently applying g-NK cells to hematologic cancers in an ongoing Phase 1 trial enrolling patients with non-Hodgkin’s lymphoma, multiple myeloma and acute myelogenous leukemia.
  • To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors, with low donor to donor variability.

Indapta Therapeutics Awarded $4.5 Million by CPRIT to Advance Clinical Development of its Allogenic Natural Killer Cell Therapy

Retrieved on: 
tisdag, maj 21, 2024
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Genetic engineering, Interleukin, Patient, ADCC, Cytokine, NK, Clinical trial, Therapy, IND, Rituximab, Safety, Lymphoma, Multiple sclerosis, Cancer, Research, Multiple myeloma, Cytomegalovirus, CMV, Research institute, Cell, NKG2C

The $4.5 million grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.

Key Points: 
  • The $4.5 million grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.
  • “We greatly appreciate that CPRIT has recognized the promise of Indapta’s allogeneic g-NK cell therapy for the treatment of advanced cancer patients,” said Dr. Mark Frohlich, CEO of Indapta.
  • Indapta’s universal, allogeneic NK cell therapy platform consists of a potent subset of naturally occurring NK cells, known as “g minus” NK cells, or “g-NK” cells.
  • To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors, with low donor to donor variability.

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design

Retrieved on: 
tisdag, maj 14, 2024
Biotechnology, Health, Pharmaceutical, Technology, Artificial Intelligence, Doctor of Philosophy, Protein, Translation, Cytokine, Drug development, G protein-coupled receptor, Language, Eurosport 1, Harvard University, Senior, AI, Khosla Ventures, Medicine, Therapy, Nabla, AstraZeneca, Nature Methods, Multimedia, Antibody, Synthetic media, Drug design

View the full release here: https://www.businesswire.com/news/home/20240514763517/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240514763517/en/
    Nabla Bio Co-Founders Surge Biswas and Frances Anastassacos at the company's labs in Cambridge, Mass.
  • Nabla’s generative protein design platform is unlocking hundreds of these previously inaccessible targets by enabling the precise design of conformation- and target-selective antibody binders.
  • Across its collaborations, Nabla has demonstrated the broad applicability of its platform, beyond drug design for multipass membrane proteins.
  • These results are an important step in translating generative protein design to clinical therapies and evidence of Nabla’s expanding capabilities.

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Retrieved on: 
torsdag, maj 9, 2024
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Mantle cell lymphoma, Cancer, International Society, Investment, Cell, Phenotype, Safety, Risk, Pharmacokinetics, Poster, Lymphoproliferative disorders, Depreciation, Cytokine, Partnership, Lymphoma, Biologics license application, ATRA, Follicular lymphoma, CD19, ASH, Epstein–Barr virus, Patient, NHL, LD, Toxicity, BLA, Memory, Workforce, EBV, Biomarker, SLE, Tabelecleucel, Pharmaceutical industry

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.
  • “This is anticipated to provide multiple near-term clinical milestones for ATA3219, including initial non-Hodgkin’s lymphoma data expected in the fourth quarter 2024, and initial lupus nephritis data in the first half of 2025, with plans to expand into a new SLE cohort without lymphodepletion.
  • Subjects will receive lymphodepletion treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.